Glycan Analysis Made Easier: Hzymes N-Glycan Analysis Kit (2-AB + SPE) for Accurate Glycoform Profiling

Introduction

Many biopharmaceutical products—including monoclonal antibodies (mAbs), fusion proteins, growth factors, cytokines, therapeutic enzymes, and hormones—are glycoproteins. Proper glycosylation is critical for the solubility, stability, pharmacokinetics (PK), pharmacodynamics (PD), biological activity, and safety of therapeutic proteins, particularly with respect to immunogenicity.[1]

Protein glycosylation is influenced by both host cell type and bioprocessing conditions.[2] Different expression systems, such as mammalian cells, yeast, plants, and transgenic animals, generate distinct glycan profiles (Figure 1C). While mammalian cells typically produce human-like glycans, they may also introduce potentially immunogenic non-human glycoforms such as Neu5Gc and α-Gal. In contrast, yeast expression systems often generate high-mannose glycans.[3]

The glycosylation process results in both macroheterogeneity and microheterogeneity, leading to diverse glycoforms on proteins with identical amino acid sequences.[4] Therefore, comprehensive glycosylation analysis is essential for ensuring the quality, efficacy, consistency, and safety of biopharmaceutical products.

Figure 1. Examples of N-glycans identified in recombinant glycoproteins.

(A) Therapeutic humanized IgG1 monoclonal antibody

(B) Recombinant human erythropoietin (rhEPO)

Hzymes N-Glycan Analysis Kit (2-AB + SPE)

The Hzymes N-Glycan Analysis Kit (2-AB + SPE) combines the proven advantages of traditional 2-aminobenzamide (2-AB) fluorescent labeling with solid-phase extraction (SPE) purification technology, a method widely recommended by pharmacopoeias and industry guidelines.

This integrated workflow offers:

Convenient and streamlined operation
Excellent reproducibility and stability
High specificity and sensitivity
Robust analytical performance
Regulatory-friendly glycan analysis workflow

The kit provides a reliable, end-to-end solution for N-glycan profiling in biopharmaceutical development and quality control.

Performance Evaluation

1. Specificity: No Interfering Peaks Detected

Blank samples showed no interfering peaks at the retention times corresponding to positive samples, demonstrating excellent assay specificity and reliable glycan detection.

2. Precision: CV < 10%

Two operators independently prepared six parallel samples, with each sample analyzed once.

Results demonstrated excellent repeatability:

Retention Time CV: < 0.2%
Peak Area CV: < 10%
Relative Peak Area (Area%) CV: < 2%

Table 1. 96-Well Plate Method

Table 2. SPE Cartridge Method

Chromatograms from all 12 samples showed high overlap and excellent consistency.

3. Lot-to-Lot Consistency: CV < 5%

Three independent manufacturing batches of the kit were evaluated. Samples were processed separately using each batch, with three replicates per batch.

Results showed:

Peak Area CV: < 5%
Relative Peak Area (Area%) CV: < 2%

Table 3. 96-Well Plate Method

Table 4. SPE Cartridge Method

These data confirm strong batch-to-batch reproducibility and manufacturing consistency.

4. Linearity: R² ≥ 0.99

Six concentration levels were prepared and analyzed using both the 96-well plate and SPE cartridge workflows.

Excellent linearity was achieved across the tested range:

96-Well Plate Workflow: R² > 0.99
SPE Cartridge Workflow: R² > 0.99

Figure 6. Linearity Results – 96-Well Plate

Figure 7. Linearity Results – SPE Cartridge

5. Method Comparison: Comparable Performance to Magnetic Bead Purification

Complex biologic samples including:

Trastuzumab

Cadonilimab

Etanercept

were analyzed using both the Hzymes SPE purification workflow (96-well plate and SPE cartridge formats) and a magnetic bead-based purification method.

Two replicates were tested for each sample.

Results demonstrated that glycan profiles generated using the SPE workflow were highly consistent with those obtained using magnetic bead purification, confirming the accuracy and reliability of the Hzymes method.

Why Choose the Hzymes N-Glycan Analysis Kit (2-AB + SPE)?

✔ Pharmacopoeia-aligned SPE purification workflow
✔ Proven 2-AB labeling chemistry for robust glycan detection
✔ High specificity with no interfering peaks
✔ Excellent precision and batch consistency
✔ Strong linearity (R² ≥ 0.99)
✔ Comparable performance to magnetic bead purification methods
✔ Suitable for monoclonal antibodies, fusion proteins, cytokines, and other glycoprotein therapeutics

Applications

Biopharmaceutical glycosylation characterization
Monoclonal antibody glycan profiling
Biosimilar comparability studies
Process development and optimization
Quality control and batch release testing
Regulatory submission support

References

［1］Jefferis R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci 2009; 30:356–62; PMID:19552968;

［2］Hossler P, Khattak SF, Li ZJ. Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology 2009; 19:936–49; PMID:19494347;

［3］Houdebine LM. Production of pharmaceutical proteins by transgenic animals. Comp Immunol Microbiol Infect Dis 2009; 32:107–21;

［4］Beck A, Debaene F, Diemer H, Wagner-Rousset E, Colas O, Dorsselaer AV, Cianferani S. Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies. J Mass Spectrom 2015; 50:285–97;

［5］国家药典委员会. 中华人民共和国药典（2025年版）三部[S]. 北京: 中国医药科技出版社, 2025.